Skip to main content
α
中文

AI-generated · Based on company filings and platform data · Not investment advice

Earnings Brief PFE

Pfizer (PFE) Q3 2026 Earnings Brief: Revenue $16.58B, −0.4% YoY

Released Nov 3, 2026 (ET)

Quarter: Q3 2026, period ended 2026-09-30; released 2026-11-03 (ET).

In one line: Pfizer's revenue in the third quarter of 2026 was US$16.58 billion, with adjusted EPS of US$0.87 exceeding analysts' consensus estimate of US$0.74, and year-on-year revenue was basically the same.

Key numbers

MetricThis quarterNote
Revenue$16.58BYoY −0.4%
Adj. EPS vs consensus$0.87 vs $0.74Beat (+18.3%)
GAAP diluted EPS$0.56Different basis from consensus
Net margin19.6%Net income $3.24B
Next-quarter EPS consensus$0.6918 analysts; revenue consensus $17.22B

Three things to know

1. Cost optimization plan advances

The company said it announced approximately $1 billion in new net cost savings in the third quarter of 2026, resulting from technology and process simplification in commercial, R&D and support functions, and is expected to be gradually realized from 2027 to 2029. Relevant one-time expenditures are expected to reach US$2 billion and will be completed by 2029.

2. Manufacturing optimization leads to long-term savings

The company has launched the next phase of its manufacturing optimization plan, which is expected to bring approximately US$1.5 billion in additional cost savings from 2027 to 2029, mainly through network structure adjustment, product portfolio optimization and operational efficiency improvements. One-time costs to achieve this goal are expected to be $4 billion, of which approximately 60% will be non-cash expenses.

3. Core product revenue growth offsets decline in epidemic products

Total revenue for the quarter fell 0.4% year-on-year, but after excluding the new crown products Comirnaty and Paxlovid, operating income increased 7% year-on-year. Growth mainly comes from products such as Eliquis, Padcev, Vyndaqel series, Nurtec ODT/Vydura and Lorbrena.

Market reaction

Results were released on 2026-11-03 (ET). From the last pre-report close (2026-11-02, $30.23) to the close of the first session after the report (2026-11-04, $30.35), the stock moved +0.39%. The report-day close was $29.57; the next session closed +2.63% from it (for after-hours releases, this leg better reflects the reaction to the report).

What to watch next

  • Pay attention to the reflection of cost savings in the fourth quarter financial report of 2027.
  • Observe the actual progress of one-time expenditures related to manufacturing optimization projects from 2027 to 2029.
  • Watch for further explanation from management on the sustainability of growth in the non-COVID-19 product line in subsequent reports.
  • Next report date (platform calendar): 2027-02-02

Sources

  • Financials: fundamentals-svc (EDGAR filings, analyst consensus)
  • Prices: fundamentals-svc /v1/candles-ondemand
  • MD&A source: 10-Q (filed 2026-11-03)
  • Company press release (8-K): SEC EDGAR

Read the Pfizer (PFE) stock report →

← All earnings briefs